Literature DB >> 18480302

RANKL is a mediator of bone resorption in idiopathic hypercalciuria.

Samirah Abreu Gomes1, Luciene Machado dos Reis, Irene Lourdes Noronha, Vanda Jorgetti, Ita Pfeferman Heilberg.   

Abstract

BACKGROUND AND OBJECTIVES: This study aimed to determine the expression of osteoprotegerin, receptor activator of nuclear factor kappaB ligand, interleukin-1alpha, transforming growth factor-beta, and basic fibroblast growth factor in stone-forming patients with idiopathic hypercalciuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunohistochemical analysis was performed in undecalcified bone samples previously obtained from 36 transiliac bone biopsies of patients who had idiopathic hypercalciuria and whose histomorphometry had shown lower bone volume, increased bone resorption, and prolonged mineralization lag time.
RESULTS: Bone expression of receptor activator of nuclear factor kappaB ligand and osteoprotegerin was significantly higher in patients with idiopathic hypercalciuria versus control subjects. Transforming growth factor-beta immunostaining was lower in patients with idiopathic hypercalciuria than in control subjects and correlated directly with mineralization surface. Interleukin-1alpha and basic fibroblast growth factor staining did not differ between groups. Receptor activator of nuclear factor kappaB ligand bone expression was significantly higher in patients who had idiopathic hypercalciuria and exhibited higher versus normal bone resorption.
CONCLUSION: A higher expression of receptor activator of nuclear factor kappaB ligand in bone tissue suggests that increased bone resorption in patients with idiopathic hypercalciuria is mediated by receptor activator of nuclear factor kappaB ligand. Osteoprotegerin bone expression might have been secondarily increased in an attempt to counteract the actions of receptor activator of nuclear factor kappaB ligand. The low bone expression of transforming growth factor-beta could contribute to the delayed mineralization found in such patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480302      PMCID: PMC2518782          DOI: 10.2215/CJN.00240108

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  49 in total

1.  Brazilian normal static bone histomorphometry: effects of age, sex, and race.

Authors:  Luciene M Dos Reis; João R Batalha; Daniel R Muñoz; Aurélio Borelli; Pedro H S Correa; Aluizio B Carvalho; Vanda Jorgetti
Journal:  J Bone Miner Metab       Date:  2007-10-25       Impact factor: 2.626

Review 2.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Authors:  N Udagawa; N Takahashi; E Jimi; K Matsuzaki; T Tsurukai; K Itoh; N Nakagawa; H Yasuda; M Goto; E Tsuda; K Higashio; M T Gillespie; T J Martin; T Suda
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

4.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Authors:  V Kartsogiannis; H Zhou; N J Horwood; R J Thomas; D K Hards; J M Quinn; P Niforas; K W Ng; T J Martin; M T Gillespie
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

5.  Bone disease in idiopathic hypercalciuria.

Authors:  Ita P Heilberg; José R Weisinger
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-07       Impact factor: 2.894

6.  Increased osteoblastic activity and expression of receptor activator of NF-kappaB ligand in nonuremic nephrotic syndrome.

Authors:  Michael Freundlich; Evelyn Alonzo; Ezequiel Bellorin-Font; Jose R Weisinger
Journal:  J Am Soc Nephrol       Date:  2005-05-11       Impact factor: 10.121

7.  Effect of dietary modification on urinary stone risk factors.

Authors:  Charles Y C Pak; Clarita V Odvina; Margaret S Pearle; Khashayar Sakhaee; Roy D Peterson; John R Poindexter; Linda J Brinkley
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

8.  Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria.

Authors:  H J Heller; J E Zerwekh; F A Gottschalk; C Y C Pak
Journal:  Kidney Int       Date:  2007-02-21       Impact factor: 10.612

Review 9.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

Authors:  Angela Rogers; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2005-08-16       Impact factor: 5.958

10.  Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry.

Authors:  Samirah Abreu Gomes; Luciene Machado dos Reis; Ivone Braga de Oliveira; Irene de Lourdes Noronha; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

View more
  13 in total

1.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

2.  Bisphosphonates in the management of idiopathic hypercalciuria associated with osteoporosis: a new trick from an old drug.

Authors:  Gerolamo Bianchi; Andrea Giusti; Giulio Pioli; Antonella Barone; Ernesto Palummeri; Giuseppe Girasole
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

3.  Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria.

Authors:  Emmanuel Letavernier; Olivier Traxer; Michel Daudon; Mohammed Tligui; Jérôme Hubert-Brierre; Dominique Guerrot; Aline Sebag; Laurent Baud; Jean-Philippe Haymann
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

Review 4.  Idiopathic hypercalciuria and bone health.

Authors:  Laura E Ryan; Steven W Ing
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

Review 5.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

6.  Association of vitamin D receptor gene polymorphism and calcium urolithiasis in the Chinese Han population.

Authors:  Shuai Wang; Xiao Wang; Jian Wu; Yiwei Lin; Hong Chen; Xiangyi Zheng; Cheng Zhou; Liping Xie
Journal:  Urol Res       Date:  2011-11-25

7.  Plasma and urinary levels of cytokines in patients with idiopathic hypercalciuria.

Authors:  Augusto C S Santos; Eleonora M Lima; Maria Goretti M G Penido; Katia D Silveira; Mauro M Teixeira; Eduardo A Oliveira; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2012-01-07       Impact factor: 3.714

8.  Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study.

Authors:  Maria Pavlou; Vasileios Giapros; Anna Challa; Nikolaos Chaliasos; Ekaterini Siomou
Journal:  Pediatr Nephrol       Date:  2018-07-25       Impact factor: 3.714

Review 9.  Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formers.

Authors:  Daniel A Wollin; Adam G Kaplan; Glenn M Preminger; Pietro Manuel Ferraro; Antonio Nouvenne; Andrea Tasca; Emanuele Croppi; Giovanni Gambaro; Ita P Heilberg
Journal:  Asian J Urol       Date:  2018-06-26

10.  Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.

Authors:  Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji
Journal:  BMC Nephrol       Date:  2018-07-11       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.